Novavax shares up on fourth quarter earnings beat

Investing.com

02-27

Investing.com -- Shares of Novavax (NASDAQ:NVAX) rose about 1.75% in premarket trading after reporting a smaller-than-expected quarterly loss but it missed revenue estimates. The company is transitioning away from direct commercialization of its COVID-19 vaccine.

The vaccine maker posted a fourth-quarter loss per share of $0.51, beating analysts’ expectations of a 60-cent loss on each share. Revenue came in at $88.31 million, below the consensus estimate of $102.74 million.

Novavax said it was transitioning away from commercial responsibilityof its COVID-19 vaccine, Nuvaxovid, giving it to Sanofi (NASDAQ:SNY) starting with the 2025-2026 season.

The company also secured a $50 million milestone payment under its Sanofi agreement and completed the $200 million sale of its Czech Republic manufacturing facility to Novo Nordisk (NYSE:NVO), a move expected to reduce annual costs by about $80 million.

The company ended 2024 with over $1 billion in cash and accounts receivables and provided 2025 financial guidance. CEO John C. Jacobs said Novavax is shifting its focus toward pipeline expansion and partnerships for its vaccine candidates and adjuvant technology.

Related Articles

Novavax shares up on fourth quarter earnings beat

India's economic growth faces challenges, IMF suggests reforms

Goldman Sachs tweaks its diversity policy

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2514438388"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514438388\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2514438388?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 22:25","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2514438388","market":"us","top_or_hot":-1,"title":"Novavax shares up on fourth quarter earnings beat","media":"Investing.com","content":"<html><body><p>Investing.com -- Shares of Novavax (NASDAQ:NVAX) rose about 1.75% in premarket trading after reporting a smaller-than-expected quarterly loss but it missed revenue estimates. The company is transitioning away from direct commercialization of its COVID-19 vaccine.</p>\n<p>The vaccine maker posted a fourth-quarter loss per share of $0.51, beating analysts’ expectations of a 60-cent loss on each share. Revenue came in at $88.31 million, below the consensus estimate of $102.74 million.</p>\n<p>Novavax said it was transitioning away from commercial responsibilityof its COVID-19 vaccine, Nuvaxovid, giving it to <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> (NASDAQ:SNY) starting with the 2025-2026 season. <br/><br/>The company also secured a $50 million milestone payment under its Sanofi agreement and completed the $200 million sale of its Czech Republic manufacturing facility to Novo Nordisk (NYSE:NVO), a move expected to reduce annual costs by about $80 million.</p>\n<p>The company ended 2024 with over $1 billion in cash and accounts receivables and provided 2025 financial guidance. CEO John C. Jacobs said Novavax is shifting its focus toward pipeline expansion and partnerships for its vaccine candidates and adjuvant technology.</p>\n<p>Related Articles</p>\n<p>Novavax shares up on fourth quarter earnings beat</p>\n<p>India's economic growth faces challenges, IMF suggests reforms</p>\n<p>Goldman Sachs tweaks its diversity policy</p>\n</body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Novavax shares up on fourth quarter earnings beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax shares up on fourth quarter earnings beat\n</h2>\n<h4 class=\"meta\">\n</h4><p class=\"head\">\n<strong class=\"h-name small\">Investing.com</strong><span class=\"h-time small\">2025-02-27 22:25</span>\n</p>\n</header>\n<article>\n<p>Investing.com -- Shares of Novavax (NASDAQ:NVAX) rose about 1.75% in premarket trading after reporting a smaller-than-expected quarterly loss but it missed revenue estimates. The company is transitioning away from direct commercialization of its COVID-19 vaccine.</p>\n<p>The vaccine maker posted a fourth-quarter loss per share of $0.51, beating analysts’ expectations of a 60-cent loss on each share. Revenue came in at $88.31 million, below the consensus estimate of $102.74 million.</p>\n<p>Novavax said it was transitioning away from commercial responsibilityof its COVID-19 vaccine, Nuvaxovid, giving it to <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> (NASDAQ:SNY) starting with the 2025-2026 season. <br/><br/>The company also secured a $50 million milestone payment under its Sanofi agreement and completed the $200 million sale of its Czech Republic manufacturing facility to Novo Nordisk (NYSE:NVO), a move expected to reduce annual costs by about $80 million.</p>\n<p>The company ended 2024 with over $1 billion in cash and accounts receivables and provided 2025 financial guidance. CEO John C. Jacobs said Novavax is shifting its focus toward pipeline expansion and partnerships for its vaccine candidates and adjuvant technology.</p>\n<p>Related Articles</p>\n<p>Novavax shares up on fourth quarter earnings beat</p>\n<p>India's economic growth faces challenges, IMF suggests reforms</p>\n<p>Goldman Sachs tweaks its diversity policy</p>\n<div class=\"bt-text\">\n<p> 來源：<a href=\"https://finance.yahoo.com/news/novavax-shares-fourth-quarter-earnings-142515939.html\">Investing.com</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"諾瓦瓦克斯醫藥","start_time":0,"source_url":"https://finance.yahoo.com/news/novavax-shares-fourth-quarter-earnings-142515939.html","article_id":"2514438388","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514438388","pubTimestamp":1740666315,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Investing.com --Shares of Novavax  rose about 1.75% in premarket trading after reporting a smaller-than-expected quarterly loss but it missed revenue estimates. The company is transitioning away from direct commercialization of its COVID-19 vaccine.The vaccine maker posted a fourth-quarter loss per share of $0.51, beating analysts’ expectations of a 60-cent loss on each share. Revenue came in at $88.31 million, below the consensus estimate of $102.74 million.Novavax said it was transitioning away from commercial responsibilityof its COVID-19 vaccine, Nuvaxovid, giving it to Sanofi  starting with the 2025-2026 season. The company also secured a $50 million milestone payment under its Sanofi agreement and completed the $200 million sale of its Czech Republic manufacturing facility to Novo Nordisk , a move expected to reduce annual costs by about $80 million.The company ended 2024 with over $1 billion in cash and accounts receivables and provided 2025 financial guidance. CEO John C. Jacob","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","SNY":"赛诺菲安万特"},"translate_title":"Novavax股价因第四季度盈利超出预期而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":1,"SNY":0.9},"content_text":"Investing.com -- Shares of Novavax (NASDAQ:NVAX) rose about 1.75% in premarket trading after reporting a smaller-than-expected quarterly loss but it missed revenue estimates. The company is transitioning away from direct commercialization of its COVID-19 vaccine.\nThe vaccine maker posted a fourth-quarter loss per share of $0.51, beating analysts’ expectations of a 60-cent loss on each share. Revenue came in at $88.31 million, below the consensus estimate of $102.74 million.\nNovavax said it was transitioning away from commercial responsibilityof its COVID-19 vaccine, Nuvaxovid, giving it to Sanofi (NASDAQ:SNY) starting with the 2025-2026 season. The company also secured a $50 million milestone payment under its Sanofi agreement and completed the $200 million sale of its Czech Republic manufacturing facility to Novo Nordisk (NYSE:NVO), a move expected to reduce annual costs by about $80 million.\nThe company ended 2024 with over $1 billion in cash and accounts receivables and provided 2025 financial guidance. CEO John C. Jacobs said Novavax is shifting its focus toward pipeline expansion and partnerships for its vaccine candidates and adjuvant technology.\nRelated Articles\nNovavax shares up on fourth quarter earnings beat\nIndia's economic growth faces challenges, IMF suggests reforms\nGoldman Sachs tweaks its diversity policy","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}